P-GLYCOPROTEIN EXPRESSION AND FUNCTION IN HIV+ WOMEN
HIV 女性中 P-糖蛋白的表达和功能
基本信息
- 批准号:6660135
- 负责人:
- 金额:$ 20.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-04-01 至 2003-03-31
- 项目状态:已结题
- 来源:
- 关键词:HIV infections P glycoprotein adult human (21+) age difference antiAIDS agent cytochrome P450 female flow cytometry fluorescent dye /probe gene expression hormone regulation /control mechanism human immunodeficiency virus human subject lymphocyte menopause multidrug resistance ovulation patient oriented research pharmacokinetics protease inhibitor protein localization protein structure function racial /ethnic difference sex hormones tissue /cell culture women's health
项目摘要
Description (Abstract Provided by Applicant): We hypothesize that gender,
ovulatory function and disease may affect P-glycoprotein (P-gp) expression in
the intestine and other organs such as the liver, endometrium and lymphocytes,
thereby modulating the effectiveness of protease inhibitors (PIs) in HIV+
women. P-gp expression and function varies with ovulatory function and phase.
The highest levels occur during menopause and in the midluteal phase of the
cycle; the severity of disease can also influence P-gp activity in various
tissues in women (liver, gut, lymphocytes and endometrium).
This in turn can affect the pharmacokinetics and pharmacodynamics of protease
inhibitors (PIs) as well as the progression of HIV disease. While differences
in pharmacokinetics of drugs that are cytochrome P4503A (CYP3A) and P-gp
substrates, such as the PIs, are manifested as differences in metabolism, we
believe that this end result is regulated by differences in P-gp function and
activity rather than by differences in CYP3A expression across the population.
Project IV has five specific aims: I) to determine if the intestine, like the
liver and endometrium, exhibits variable levels of transporter and enzyme that
are regulated by progestins and/or estrogen, (which will also serve as a
measure as to how well commonly used cell lines, e.g., liver and endometrium,
exhibit characteristics that may be useful in testing the hypothesis); 2) to
learn whether an assay in lymphocytes might be used as a simple model for what
occurs in the endometrium, intestine and liver; 3) to test whether known
differences in P-gp between premenopausal and postmenopausal women translate
into differences in PI drug levels; 4) to correlate ovulatory cycle phase
(early follicular, midluteal and postmenopausal) and/or P1 levels with markers
of viral resistance; and 5) to determine the effects of four parameters: (a)
stage of ovulatory cycle phase (early follicular. midluteal or
postmenopausal), (b) ethnicity (particularly African American vs. Caucasian),
(c) presence vs. absence of HIV infection, and (d) CD4 count strata on P-gp
expression, as measured by quantitative analysis of P-gp in tissue biopsies
(intestinal cells, endometrium and peripheral blood mononuclear cells) and
P-gp function, as measured by PT pharmacokinetic profiles.
描述(申请人提供的摘要):我们假设性别,
排卵功能和疾病可能会影响P-糖蛋白(P-gp)表达,
肠和其他器官如肝脏、子宫内膜和淋巴细胞,
从而调节蛋白酶抑制剂(PI)在HIV+
妇女P-gp的表达和功能随排卵功能和排卵时相而变化。
最高水平发生在绝经期和黄体中期,
疾病的严重程度也会影响P-gp活性,
女性的组织(肝脏、肠道、淋巴细胞和子宫内膜)。
这反过来又会影响蛋白酶的药代动力学和药效学
抑制剂(PI)以及HIV疾病的进展。虽然差异
细胞色素P4503 A(CYP 3A)和P-gp药物的药代动力学
底物,如PI,表现为代谢的差异,我们
认为这一最终结果是由P-gp功能的差异调节的,
活性而不是整个人群中CYP 3A表达的差异。
第四个项目有五个具体目标:一)确定肠道,如
肝脏和子宫内膜,表现出不同水平的转运蛋白和酶,
受孕激素和/或雌激素的调节,(这也将作为一种
测量常用的细胞系,例如,肝脏和子宫内膜,
表现出可能有助于检验假设的特征); 2)
了解淋巴细胞中的检测是否可以用作一个简单的模型,
发生在子宫内膜、肠道和肝脏; 3)测试是否已知
绝经前和绝经后妇女之间P-gp的差异
PI药物水平的差异; 4)与排卵周期相关联
(卵泡早期、黄体中期和绝经后)和/或P1水平与标志物
病毒抗性;和5)确定四个参数的影响:(a)
排卵周期阶段(卵泡早期)。黄体中期或
绝经后),(B)种族(特别是非裔美国人对高加索人),
(c)存在与不存在HIV感染,以及(d)P-gp的CD 4计数分层
表达,通过组织活检中P-gp的定量分析测定
(肠细胞、子宫内膜和外周血单核细胞)和
P-gp功能,通过PT药代动力学曲线测量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LESLIE Z BENET其他文献
LESLIE Z BENET的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LESLIE Z BENET', 18)}}的其他基金
A Transporter-Based Predictive ADME Platform
基于转运蛋白的预测 ADME 平台
- 批准号:
7804736 - 财政年份:2010
- 资助金额:
$ 20.59万 - 项目类别:
Transporter-Enzyme Interplay Evaluation via Microfluidiic HTS Cell Culture Device
通过微流控 HTS 细胞培养装置评估转运蛋白-酶相互作用
- 批准号:
7429824 - 财政年份:2006
- 资助金额:
$ 20.59万 - 项目类别:
Transporter-Enzyme Interplay Evaluation via Microfluidiic HTS Cell Culture Device
通过微流控 HTS 细胞培养装置评估转运蛋白-酶相互作用
- 批准号:
7012396 - 财政年份:2006
- 资助金额:
$ 20.59万 - 项目类别:
Transporter-Enzyme Interplay Evaluation via Microfluidiic HTS Cell Culture Device
通过微流控 HTS 细胞培养装置评估转运蛋白-酶相互作用
- 批准号:
7244054 - 财政年份:2006
- 资助金额:
$ 20.59万 - 项目类别:
Cyclosporine in Diabetic Renal Transplantation
环孢素在糖尿病肾移植中的应用
- 批准号:
6972242 - 财政年份:2004
- 资助金额:
$ 20.59万 - 项目类别:
P-Gp Expression and Function in Treatment of HIV+ Women
P-Gp 在 HIV 女性治疗中的表达和功能
- 批准号:
6972257 - 财政年份:2004
- 资助金额:
$ 20.59万 - 项目类别:
P-GLYCOPROTEIN EXPRESSION AND FUNCTION IN HIV+ WOMEN
HIV 女性中 P-糖蛋白的表达和功能
- 批准号:
6579420 - 财政年份:2002
- 资助金额:
$ 20.59万 - 项目类别:
Pharmacokinetic interactions: digoxin /grapefruit juice
药代动力学相互作用:地高辛/葡萄柚汁
- 批准号:
6566746 - 财政年份:2001
- 资助金额:
$ 20.59万 - 项目类别:
EFFECT OF INTESTINAL TRANSPORTERS ON BIOAVAILABILITY OF DIURETIC FUROSEMIDE
肠道转运蛋白对利尿剂呋塞米生物利用度的影响
- 批准号:
6566772 - 财政年份:2001
- 资助金额:
$ 20.59万 - 项目类别:
相似国自然基金
P-glycoprotein与Rack1和Src相互作用并促进耐药乳腺癌细胞侵袭转移的分子机制研究
- 批准号:81472474
- 批准年份:2014
- 资助金额:85.0 万元
- 项目类别:面上项目
相似海外基金
Inhibition or evasion of P-glycoprotein-mediated drug transport
抑制或逃避 P-糖蛋白介导的药物转运
- 批准号:
10568723 - 财政年份:2023
- 资助金额:
$ 20.59万 - 项目类别:
Physiological function of P-glycoprotein in sanctuary tissue barriers in teleosts
P-糖蛋白在硬骨鱼保护区组织屏障中的生理功能
- 批准号:
RGPIN-2020-04905 - 财政年份:2022
- 资助金额:
$ 20.59万 - 项目类别:
Discovery Grants Program - Individual
Studies of P-glycoprotein Drug Interactions - Administrative Supplement for Undergraduate Summer Research
P-糖蛋白药物相互作用的研究 - 本科生暑期研究行政补充
- 批准号:
10810072 - 财政年份:2022
- 资助金额:
$ 20.59万 - 项目类别:
Bacterial targeting of the P-glycoprotein/endocannabinoid axis for reducing intestinal inflammation in ulcerative colitis
细菌靶向 P-糖蛋白/内源性大麻素轴以减少溃疡性结肠炎的肠道炎症
- 批准号:
10537517 - 财政年份:2022
- 资助金额:
$ 20.59万 - 项目类别:
Drug, Nucleotide, and Lipid Interactions with P-glycoprotein
药物、核苷酸和脂质与 P-糖蛋白的相互作用
- 批准号:
10672242 - 财政年份:2022
- 资助金额:
$ 20.59万 - 项目类别:
Mechanisms of suicide attempts by loss of P-glycoprotein function in the blood-brain barrier
血脑屏障中 P-糖蛋白功能丧失导致自杀未遂的机制
- 批准号:
22K06774 - 财政年份:2022
- 资助金额:
$ 20.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Studies of P-glycoprotein Drug Interactions - Administrative Supplement for Equipment Purchase
P-糖蛋白药物相互作用研究-设备采购行政补充
- 批准号:
10795338 - 财政年份:2022
- 资助金额:
$ 20.59万 - 项目类别:
Physiological function of P-glycoprotein in sanctuary tissue barriers in teleosts
P-糖蛋白在硬骨鱼保护区组织屏障中的生理功能
- 批准号:
RGPIN-2020-04905 - 财政年份:2021
- 资助金额:
$ 20.59万 - 项目类别:
Discovery Grants Program - Individual